Forma Therapeutics Holdings logo
Forma Therapeutics Holdings FMTX

Quarterly report 2022-Q2
added 12-23-2023

report update icon

Forma Therapeutics Holdings Balance Sheet 2011-2026 | FMTX

Annual Balance Sheet Forma Therapeutics Holdings

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-44.7 M - - -83.4 M - - - - - - -

Long Term Debt

27.6 M - - - - - - - - - -

Long Term Debt Current

5.12 M - - - - - - - - - -

Total Non Current Liabilities

- 1.03 M 2.62 M 11.9 M - - - - - - -

Total Current Liabilities

35.1 M 31.7 M 24.9 M - - - - - - - -

Total Liabilities

62.7 M 32.7 M 26.7 M 246 M - - - - - - -

Deferred Revenue

- 1.24 M 1.24 M 203 M - - - - - - -

Retained Earnings

-230 M -57.4 M 16.7 M -54.6 M - - - - - - -

Total Assets

561 M 681 M 183 M 263 M - - - - - - -

Cash and Cash Equivalents

77.4 M 283 M 174 M - - - - - - - -

Book Value

498 M 648 M 156 M 17.6 M - - - - - - -

Total Shareholders Equity

498 M 648 M 18.2 M - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Forma Therapeutics Holdings

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - 27 M 27.6 M 26.8 M 2.87 M - - 5.21 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - 60.7 M 53.3 M 62.7 M 59.4 M 34 M - 32.7 M 32.7 M 29 M 32.7 M 26.7 M 26.7 M 26.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - 1.24 M - - 1.24 M 1.24 M 1.24 M 6.43 M - 94 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - -327 M -275 M -230 M -180 M -137 M - -57.4 M -57.4 M -1.21 M -57.4 M 16.7 M 16.7 M 16.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - 475 M 514 M 561 M 602 M 613 M - 681 M 681 M 468 M 681 M 183 M 183 M 183 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - 74.4 M 77.4 M 87.2 M 50.9 M 97.8 M 283 M 283 M 283 M 283 M 173 M 173 M 173 M - 84.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

- - 414 M 461 M 498 M 543 M 579 M - 648 M 648 M 438 M 648 M 156 M 156 M 156 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - 414 M 461 M 498 M 543 M 579 M 616 M 648 M 416 M 438 M 28.8 M 18.2 M 18.2 M 83.4 M 98.2 M -48.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Forma Therapeutics Holdings, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.56 2.01 % $ 1.06 B canadaCanada
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.79 -0.79 % $ 4.31 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
argenx SE argenx SE
ARGX
$ 703.3 0.41 % $ 25 B niderlandNiderland
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 231.03 2.23 % $ 5 B danmarkDanmark
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 4.22 2.18 % $ 105 M schweizSchweiz
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.61 0.28 % $ 8.69 B australiaAustralia
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 6.63 -0.75 % $ 182 M israelIsrael
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.36 1.13 % $ 210 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 90.54 -0.71 % $ 27.2 B germanyGermany
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Burford Capital Limited Burford Capital Limited
BUR
$ 8.05 1.64 % $ 1.31 B britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 6.05 -0.82 % $ 493 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.64 3.94 % $ 16.6 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
BioCardia BioCardia
BCDA
$ 1.27 0.79 % $ 26.9 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.51 4.86 % $ 385 M britainBritain
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.58 -0.56 % $ 7.79 B israelIsrael
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.11 - $ 33.4 M usaUSA